RxDoctor Payments DataLook up a doctor →

Mohamed Sadiq, MD

Neurology · Layton, UTNPI 1164410403

Payments from drug & device makers

$30,647in general payments, 2019–2025

Across 755 payments — averaging $40.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$17K
  • AbbVie$1K
  • UCB, Inc.$1K
  • Ares Trading SA$935
  • Argenx US, Inc.$922
  • Biogen$899
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.47$16,680
AbbVie(2 entities)81$1,056
UCB, Inc.53$1,040
Ares Trading SA11$935
Argenx US, Inc.36$922
Biogen48$899
Neurocrine Biosciences, Inc.49$885
Novartis43$772
SK Life Science, Inc.23$564
Sanofi24$519
Lilly USA, LLC27$496
Teva Pharmaceuticals USA, Inc.28$438
Bristol Myers Squibb26$435
Neurelis, Inc.17$404
TG Therapeutics, Inc.8$283
Supernus Pharmaceuticals, Inc.19$276
Takeda Pharmaceuticals U.S.A., Inc.10$257
Adamas Pharmaceuticals, Inc.16$256
Johnson & Johnson(2 entities)17$254
AstraZeneca14$254
Banner Life Sciences, LLC11$221
CSL Behring10$204
Lundbeck LLC12$194
Amneal Pharmaceuticals LLC10$188
Amgen9$170
Genentech USA, Inc.8$163
Eisai Inc.10$161
MDD US Operations, LLC6$146
Sunovion Pharmaceuticals Inc.8$130
Tanabe Pharma America, Inc.7$123
Pfizer5$112
Livanova USA, Inc.6$107
Acadia Pharmaceuticals Inc6$105
Merz Pharmaceuticals, LLC3$78
E.r. Squibb & Sons, L.L.C.4$77
ANI Pharmaceuticals, Inc.3$74
Grifols USA, LLC4$69
Cala Health, Inc.3$63
Axsome Therapeutics, Inc.3$54
Medtronic1$49
Cycle Pharmaceuticals Inc2$44
Acorda Therapeutics, Inc3$42
Averitas Pharma Inc.1$41
Catalyst Pharmaceuticals, Inc.2$39
Avion Pharmaceuticals2$36
Greenwich Biosciences, Inc.2$34
Vanda Pharmaceuticals Inc.1$34
Xeris Pharmaceuticals, Inc.2$29
Boston Scientific2$26
Arbor Pharmaceuticals, Inc.1$22
Otsuka America Pharmaceutical, Inc.1$22
Aucta Pharmaceuticals, Inc.1$22
Braemar Manufacturing, LLC1$21
Kyowa Kirin, Inc.1$19
Jazz Pharmaceuticals Inc.1$18
Avanir Pharmaceuticals, Inc.1$17
Akcea Therapeutics, Inc.1$15
Bio Products Laboratory USA, Inc.1$15
Inspire Medical Systems, Inc.1$14
GRT US Holding, Inc.1$14

How this compares

$30,647 in reported general payments places this provider in the 75th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah →

Medicare billing

Part B allowed, 2024
$77,614
Medicare patients
217
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Layton

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →